Adam Joseph Lamble, MD
Cancer and Blood Disorders Center, High-Risk Leukemia Program, Leukemia and Lymphoma Program, Oncology
On staff since August 2017
Children's Title: Attending Physician, Cancer and Blood Disorders Center
Academic Title: Assistant Professor, Pediatrics
Research Center: Ben Towne Center for Childhood Cancer Research
"It’s an honor to work at Seattle Children’s hospital because of the people who work here and the revolutionary clinical and translational research that is being conducted. But most of all, it’s a privilege to partner with families and provide individualized care for children and young adults with cancer. I have a particular interest in high-risk leukemia and utilizing immune based therapies to improve outcomes and reduce toxicity in children with cancer."
-
Adam Lamble, MD, is an attending physician at Seattle Children’s Hospital, Assistant Professor of Pediatrics at the University of Washington School of Medicine.
Dr. Lamble’s clinical and research interests focus on high-risk hematologic malignancies and immune based therapies. He is a member of the Children’s Oncology Group (COG) myeloid diseases committee and is currently leading a Phase I clinical trial for pediatric patients with multiply relapsed acute myeloid leukemia (AML). Dr. Lamble provides consultations through both the High-Risk Leukemia Clinic and the Immunotherapy Team.
-
-
Dr. Lamble is one of the best Pediatric leukemia doctor for high risk leukemia cases. He is able to create individualized treatment plans and prepare patients for transplants. He is very thorough in his research and treatment plans. Dr. lamble provides quality answers to difficult questions from parents. The amazing thing about the doctor is that he always has multiple treatment plans and options for best outcome. We were extremely lucky to get our son's treatment under Dr. Lamble.
-
Dr. Lamble has a brilliant mind and we are so thankful to him for saving our son’s life. He always made sure we were well-informed and comfortable with any treatment decision and took the time to answer our many questions. He also brought just the right touch of humor that we appreciated during an extremely stressful time. Thank you, Dr. Lamble!
-
-
Award Name Award Description Awarded By Award Date Pediatric Fellowship Research Award Oregon Health and Science University 2017 Young Investigator Award American Society of Pediatric Hematology/Oncology 2015 Alpha Omega Alpha Medical Honor Society University of Kansas Medical Center 2011 Gold Humanism Honor Society University of Kansas Medical Center 2011 -
Other Publications
-
Lamble AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, Pardo L, Sung L, Cooper TM, Kolb EA, Aplenc R, Tasian SK, Loken MR, Meshinchi SCD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
34855461 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jan. 20 : 40(3)252-261 PMCID:PMC8769096 -
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi SCEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
33951732 Blood, 2021 Sept. 30 : 138(13)1137-1147 -
Field MT, Lamble AJ, Holtzclaw SL, Tucker SA, Ketterl TGChemotherapy roadmaps in pediatric oncology: A digital electronic medical record integrated solution.
34558367 Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021 Sept. 24 : 10781552211040450 -
Leonard JT, Kosaka Y, Malla P, LaTocha D, Lamble A, Hayes-Lattin B, Byrd K, Druker BJ, Tyner JW, Chang BH, Lind EConcomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
32898857 Blood, 2021 Feb. 18 : 137(7)939-944 PMCID:PMC7918187 -
Lamble AJ, Gardner RCAR T cells for other pediatric non-B-cell hematologic malignancies.
33275678 Hematology. American Society of Hematology. Education Program, 2020 Dec. 4 : 2020(1)494-500 PMCID:PMC7727568 -
Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H 3rd, Loriaux MM, Tognon CE, Lo P, Tyner JW, Fan G, McWeeney SK, Druker BJ, Lind EFReversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
32513686 Proceedings of the National Academy of Sciences of the United States of America, 2020 June 23 : 117(25)14331-14341 PMCID:PMC7321988 -
Lamble AJ, Tasian SKOpportunities for immunotherapy in childhood acute myeloid leukemia.
31808843 Hematology. American Society of Hematology. Education Program, 2019 Dec. 6 : 2019(1)218-225 PMCID:PMC6913480 -
Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EFIntegrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.
29175391 Journal of immunological methods, 2018 Feb. : 45344-52 -
Lamble AJ, Lind EFTargeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.
29951373 Frontiers in oncology, 2018 : 8213 PMCID:PMC6008423 -
Lamble A, Phelan R, Burke MWhen Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.
28686179 Journal of clinical medicine, 2017 July 7 : 6(7) PMCID:PMC5532574 -
Lamble A, Nguyen T, Lindemulder S, Spiro D, Malempati S, Nolt D, Stork LA Clinical Pathway to Reduce Time to Antibiotic Administration in Pediatric Cancer Patients With Fever and Potential Neutropenia
Journal of Clinical Pathways, 2015 Nov. 3 : 1(2)33-42
-
-
Presentations Title Event Location Date KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy American Society for Hematology Annual Conference Atlanta, GA 2021 Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group American Society for Hematology Annual Conference San Diego, CA 2019
Overview
- Board Certification(s)
-
Pediatrics
Pediatric Hematology-Oncology
- Medical/Professional School
-
University of Kansas Medical Center, Kansas City, KS
- Residency
-
Oregon Health Sciences University School of Medici, Portland, OR
- Fellowship
-
Oregon Health & Science University-OHSU, Portland, OR
- Clinical Interests
-
High Risk Leukemia, Immunotherapy, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin lymphoma
